Mighty Therapeutics Reports Business Highlights, Barth Syndrome Commercial Launch Update, and Pipeline Progress Press Release / October 14, 2026October 30, 2026
Mighty Therapeutics Partners with the POLG Foundation to Develop Novel Preclinical Model for POLG Mitochondrial Disorders and Parkinson’s Disease Press Release / September 15, 2026September 29, 2026
Mighty Therapeutics Initiates IND-Enabling Studies of MYTX-255: a Mitochondrial-Targeted Therapeutic Candidate Press Release / September 9, 2026September 29, 2026
Mighty Therapeutics and University of Washington Team Named Milestone 2 Awardee in $101M XPRIZE Healthspan Competition Press Release / August 11, 2026September 29, 2026
Mighty Therapeutics Secures Up to $150 Million to Progress Commercial and Clinical Development of New Class of Mitochondrial Targeted Medicines Press Release / July 14, 2026September 29, 2026
Mighty Therapeutics Announces First Patient Dosed in Phase 4 Confirmatory Study of Elamipretide in Barth Syndrome Press Release / July 8, 2026September 29, 2026
Mighty Therapeutics, Formerly Stealth BioTherapeutics, Announces New Name Honoring the Mitochondrial Disease Community Press Release / June 16, 2026August 24, 2026
Stealth Biotheraputics to Present Updates on Elamipretide in Barth Syndrome and POLG Disease at Euromit 2026 Press Release / May 26, 2026August 25, 2026
Stealth BioTherapeutics Provides Commercial Launch Update and Pipeline Progress Across Mitochondrial Disease Portfolio Press Release / April 30, 2026June 25, 2026
Stealth BioTherapeutics to Present Clinical Data for Bevemipretide Eye Drops at the Association for Research in Vision and Ophthalmology 2026 Annual Meeting Press Release / April 27, 2026June 25, 2026
